Addex Therapeutics Ltd. (ADXN)
| Market Cap | 68.27M |
| Revenue (ttm) | 2.85M |
| Net Income (ttm) | -15.24M |
| Shares Out | 32.85M |
| EPS (ttm) | -0.58 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | January 22 |
| Last Price | $12.12 |
| Previous Close | $12.94 |
| Change ($) | -0.82 |
| Change (%) | -6.34% |
| Day's Open | 12.39 |
| Day's Range | 11.52 - 12.45 |
| Day's Volume | 295,005 |
| 52-Week Range | 6.19 - 21.00 |
News
Genetic Technologies (NASDAQ: GENE) shares are trading higher after the company provided an update on its COVID-19 severity risk test, saying predictive capabilities improved 100% over age and...
Addex Therapeutics (ADXN) stock is soaring higher on Thursday after announcing news concerning a clinical trial for its epilepsy drug. The post Epilepsy Drug News: Why Addex Therapeutics (ADXN...
Geneva, Switzerland, January 7, 2021 – Addex Therapeutics Ltd (SIX: ADXN and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and de...
About ADXN
Addex Therapeutics Ltd, a development-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule pharmaceutical products for central nervous system (CNS) disorders in Switzerland. The company focuses on the discovery of oral small molecule allosteric modulators of G-protein coupled receptors. Its lead programs include Dipraglurant for the treatment of Parkinson's disease levodopa-induced dyskinesia, and dystonia; ADX71149 for epilepsy and undisclosed CNS disorders; and GABAB PAM for addiction. It has license and col... [Read more...]
| Industry Pharmaceutical Preparation Manufacturing | Founded 2002 |
| CEO Tim Dyer | Employees 19 |
| Stock Exchange NASDAQ | Ticker Symbol ADXN |
Financial Performance
In 2019, ADXN's revenue was 2.76 million, a decrease of -54.29% compared to the previous year's 6.04 million. Losses were -14.78 million, 798.6% more than in 2018.